Brian J. Druker

Oncology

3181 SW Sam Jackson Park Rd
Portland, OR 97239

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 208 publications

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

Journal: Blood

Published: May 04, 2026

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

Journal: American journal of hematology

Published: April 02, 2026

NRAS knockdown reverses monocytic cell state and resensitizes resistant FLT3-AML cells to gilteritinib.

NRAS knockdown reverses monocytic cell state and resensitizes resistant FLT3-AML cells to gilteritinib.

Journal: Blood

Published: January 30, 2026

DDX41-Mutated AML: A Case Report and Perspectives.

DDX41-Mutated AML: A Case Report and Perspectives.

Journal: JCO precision oncology

Published: January 21, 2026

Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report.

Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report.

Journal: Blood advances

Published: November 19, 2025

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Journal: Blood advances

Published: November 19, 2025

Identifying Drug Combination Strategies for ZMYM2: FGFR1 Fusion Positive Leukemia.

Identifying Drug Combination Strategies for ZMYM2: FGFR1 Fusion Positive Leukemia.

Journal: Precision oncogenomics

Published: August 29, 2025

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.

Journal: Haematologica

Published: July 24, 2025

Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib.

Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib.

Journal: Science signaling

Published: July 15, 2025

Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Journal: Blood neoplasia

Published: July 02, 2025

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 12, 2025

A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.

A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.

Journal: Cancer research communications

Published: February 17, 2025

Showing 1-12 of 208

Last Updated: 09/26/2026